Managing new premium-priced medicines in Europe

Figures & data

Figure 1 Activities to manage the entry of new medicines Source: [7] (adapted from [10, 13, 14]

WHO Europe: ‘Access to new medicines in Europe: technical review of policy initiatives and opportunities for research’ 2015 WHO: Copenhagen http://www.euro.who.int/en/health-topics/Health-systems/medicines/publications2/2015/access-to-new-medicines-in-europe-technical-review-of-policy-initiatives-and-opportunities-for-collaboration-and-research available at:

 Google Scholar

MalmströmR, GodmanB, DiogeneE, BaumgärtelC, BennieM, BishopI, et al: Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol 2013, 4:39.

 PubMed Web of Science ®Google Scholar

WettermarkB, GodmanB, ErikssonC, van GanseE, GarattiniS, JoppiRet al: Einführung neuer Arzneimittel in europäische Gesundheitssysteme [Introduction of new medicines into European healthcare systems]. GGW 2010, 10(3):24–34

 Google Scholar

GodmanB, MalmströmR, DiogeneE, GrayA, JayathissaS, TimoneyAet al: Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol 2015, 8(1):77–94.

 PubMed Web of Science ®Google Scholar